Dr. GPCR Podcast

To read the full #Newsletter click here:

https://www.drgpcr.com/April-2022/

-------------------------------------------

Become a #DrGPCR Ecosystem Member

-------------------------------------------

Imagine a world in which the vast majority of us are healthy.

The #DrGPCR Ecosystem is all about dynamic interactions between us who are working towards exploiting the druggability of #GPCR's. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.

To build our #GPCR Ecosystem, we created various enabling outlets.

-------------------------------------------

Are you a #GPCR professional? 

For more details, visit the #DrGPCR Podcast Episode #74 page

http://www.drgpcr.com/episode-74-with-dr-daniel-wacker/

-------------------------------------------

I obtained my B.Sc. degree from the University of Munich performing work in the lab of Dr. Roland Beckmann with a brief stay at Cambridge University, UK, working in the lab of the late Dr. Kiyoshi Nagai. I then obtained an M.Sc. at the University in Munich working e.g. in the lab of Patrick Cramer. I next moved to Rockefeller University in NYC to work in the lab of the late Dr. Guenter Blobel, before starting my Ph.D. in 2009 at The Scripps Research Institute in La Jolla. There I obtained my Ph.D. in the lab of Dr. Ray Stevens in 2013 solving several GPCR crystal structures, including that of the first serotonin receptor. I then moved to UNC at Chapel Hill to do postdoctoral work in the lab of Dr. Bryan Roth where I established GPCR structural biology and learned the ins and outs of molecular pharmacology and in vitro drug discovery. In 2018 I started my own lab at the Icahn School of Medicine at Mount Sinai in NYC, where I have been working on structure-function and drug discovery of GPCRs and transporters.

-------------------------------------------

We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.

Fill out the Ecosystem waitlist form today to be the first to explore our brand new and improved space!

For more details, visit our website http://www.DrGPCR.com/Ecosystem/

-------------------------------------------

Dr. Aylin Hanyaloglu has been a Principal Investigator at Imperial College London since 2007. She received her BSc in Human Biology from King’s College London in 1997, and while her Ph.D. commenced at the MRC Human Reproductive Sciences Centre, Edinburgh, a move to Perth, Australia resulted in her Ph.D. in Molecular Endocrinology being awarded in 2002 with Distinction from the University of Western Australia.

-------------------------------------------

We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.

Fill out the Ecosystem waitlist form today to be the first to explore our brand new and improved space!

For more details, visit our website http://www.DrGPCR.com/Ecosystem/.

-------------------------------------------

Are you a #GPCR professional?

- Register to become a Virtual Cafe speaker

http://www.drgpcr.com/virtual-cafe/

-   Subscribe to our Monthly Newsletter

http://www.drgpcr.com/newsletter/

-   Listen and subscribe to #DrGPCR Podcasts

http://www.drgpcr.com/podcast/

-   Support #DrGPCR Ecosystem with your Donation.

http://www.drgpcr.com/sponsors/

-   Reserve your spots for the next #DrGPCR Virtual Cafe

http://www.drgpcr.com/virtual-cafe/

-   Watch recorded #DRGPCR Virtual Cafe presentations:

https://www.youtube.com/channel/UCJvKL3smMEEXBulKdgT_yCw

-   Share your feedback with us:

http://www.drgpcr.com/audience-survey/

-------------------------------------------

About Dr. Stuart Maudsley

Stuart graduated from the University of Leeds in the U.K. with a First Class Honors degree in Pharmacology. At the end of his studies, he was awarded the Pfizer Prize for undergraduate research. He then completed his Ph.D. at Leeds as well as the University’s Ackroyd, Brotherton, and Brown Scholar.

Following his Ph.D., Dr. Maudsley was awarded a Howard Hughes Medical Institute Fellowship to train with Professor Robert Lefkowitz at Duke University. Following this tremendous experience, he was recruited to be the Principal Investigator of the Receptor Biology Section at the Medical Research Council (MRC) -Human Reproductive Sciences Unit within the University of Edinburgh.

At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional signaling. To broaden his biomedical skill-set Stuart next accepted the position of Head of the Receptor Pharmacology Unit at the National Institutes of Health – National Institute on Aging at the Johns Hopkins University Medical Center. At the NIH he was the recipient of the coveted NIH ‘Bench-to-Bedside’ Translational Research Grant Award, one of the few awards available within the intramural NIH program. Upon starting a new family, and returning to Europe, Dr. Maudsley continued his scientific journey with the award of the highly-valued Odysseus Program Type I Program Grant to work as both the Adjunct Director of the VIB Center for Molecular Neurology and also Vice-Chair of the Department of Biomedical Sciences at the University of Antwerp.

Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics that interdict diseases based on their gerontological underpinnings. This research stream is now forming the basis of a new technology-based start-up company, HeptOME, to help screen and develop novel longevity/disease-regulating compounds with multidimensional disease efficacy profiles.

-------------------------------------------

We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.

Fill out the Ecosystem waitlist form today to be the first to explore our brand new and improved space!

For more details, visit our website http://www.DrGPCR.com/Ecosystem/.

-------------------------------------------

Dr. Beaulieu received a Ph.D. in Neurological Sciences from McGill University and completed his post-doctoral training at Duke University. Prior to his recruitment Dr. Beaulieu was an associate professor and Canada Research Chair (Tier2) in the Department of Psychiatry and Neuroscience at Laval University.

Dr. Beaulieu’s research is aimed at understanding how cellular and molecular mechanisms regulated by psychoactive drugs intersect with genetic risk factors for mental illnesses such as schizophrenia, depression, and bipolar disorder. Dr. Beaulieu has pioneered work establishing a role for Beta-arrestin signaling in the brain in vivo and has established its importance in D2 dopamine receptors (D2R) functions. These receptors belong to the super-family of G-protein coupled receptors (GPCR), the major molecular target for drug development. In particular, D2R is the main pharmacological target of antipsychotic drugs prescribed for schizophrenia and bipolar disorders. Work by the Beaulieu Lab has demonstrated that mood stabilizer drugs (e.g. lithium) used for bipolar disorder therapy target signaling mechanisms regulated by dopamine receptors, thus providing a framework to understand how different drug classes can engage overlapping cellular mechanisms to exert their action. The Beaulieu group is presently investigating how cell surface express proteins can act as allosteric modulators of D2R signaling and explores the potential usefulness of beta-arrestins for the development of new pharmaceutical agents.

Translational validation is important to validate findings obtained from experimental models research and bridge the gap between bench and bedside. Working in collaboration with geneticists, the Beaulieu-Lab has identified interactions between cellular mechanisms engaged by D2R and psychiatric drugs with genetic risk factors implicated in schizophrenia by large whole-genome association studies (GWAS) in humans. These investigations have led to the identification of an RNA binding protein (FXR1P) involved in the regulation of protein synthesis as a potential downstream effector of the action of mood stabilizers and other psychoactive drugs.

In addition to basic research, the Beaulieu group is also actively implicated in translational research and industry collaboration to develop new drugs and drug development technology.

-------------------------------------------

We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.

Fill out the Ecosystem waitlist form today to be the first to explore our brand new and improved space!

For more details, visit our website http://www.DrGPCR.com/Ecosystem/.

https://www.drgpcr.com/episode-70-with-dr-stephen-ferguson/

-------------------------------------------

Dr. Stephen Ferguson is a Professor in the Department of Cellular and Molecular Medicine at the University of Ottawa. He did B.Sc. in biology at McGill University and received his Ph.D. under the mentorship of Dr. Brian Collier in the Department of Pharmacology and Therapeutics at McGill University (1994).

-------------------------------------------

Are you a #GPCR professional?

- Register to become a Virtual Cafe speaker

http://www.drgpcr.com/virtual-cafe/

-   Subscribe to our Monthly Newsletter

http://www.drgpcr.com/newsletter/

-   Listen and subscribe to #DrGPCR Podcasts

http://www.drgpcr.com/podcast/

-   Support #DrGPCR Ecosystem with your Donation.

http://www.drgpcr.com/sponsors/

-   Reserve your spots for the next #DrGPCR Virtual Cafe

http://www.drgpcr.com/virtual-cafe/

-   Watch recorded #DRGPCR Virtual Cafe presentations:

https://www.youtube.com/channel/UCJvKL3smMEEXBulKdgT_yCw

-   Share your feedback with us:

http://www.drgpcr.com/audience-survey/

-------------------------------------------

Dr. Stephen Ferguson is a Professor in the Department of Cellular and Molecular Medicine at the University of Ottawa. He did B.Sc. in biology at McGill University and received his Ph.D. under the mentorship of Dr. Brian Collier in the Department of Pharmacology and Therapeutics at McGill University (1994).

-------------------------------------------

Great Lakes GPCR Retreat on the web

-------------------------------------------

We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.

Fill out the Ecosystem waitlist form today to be the first to explore our brand new and improved space!

For more details, visit our website http://www.DrGPCR.com/Ecosystem/.

https://www.drgpcr.com/episode-68-with-dr-matthew-eddy/

-------------------------------------------

About Dr. Matthew Eddy

Matthew Eddy earned his BA in Chemistry from Oberlin College, where he trained with solid-state NMR expert Professor Manish Mehta. He then earned his Ph.D. in physical chemistry from the Massachusetts Institute of Technology, training under the mentorship of Prof. Robert Griffin. Following this, Dr. Eddy began learning and investigating human GPCRs while training in the laboratories of Professors Raymond Stevens and Kurt Wüthrich at The Scripps Research Institute.

-------------------------------------------

We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.

Fill out the Ecosystem waitlist form today to be the first to explore our brand new and improved space!

For more details, visit our website http://www.DrGPCR.com/Ecosystem/.

-------------------------------------------

Are you a #GPCR professional?

- Register to become a Virtual Cafe speaker

http://www.drgpcr.com/virtual-cafe/

-   Subscribe to our Monthly Newsletter

http://www.drgpcr.com/newsletter/

-   Listen and subscribe to #DrGPCR Podcasts

http://www.drgpcr.com/podcast/

-   Support #DrGPCR Ecosystem with your Donation.

http://www.drgpcr.com/sponsors/

-   Reserve your spots for the next #DrGPCR Virtual Cafe

http://www.drgpcr.com/virtual-cafe/

-   Watch recorded #DRGPCR Virtual Cafe presentations:

https://www.youtube.com/channel/UCJvKL3smMEEXBulKdgT_yCw

-   Share your feedback with us:

http://www.drgpcr.com/audience-survey/

https://www.drgpcr.com/episode-67-with-graham-ladds/

-------------------------------------------

About Dr. Graham Ladds

Graham studied Biochemistry at the University of Birmingham before completing a Ph.D. in yeast pheromone signaling at Warwick. He continued to work at Warwick as a post-doc studying pro-hormone convertases before securing a 5-year independent fellowship funded through the NHS. This project enabled him to return to his interest in GPCRs.

-------------------------------------------

We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.

Fill out the Ecosystem waitlist form today to be the first to explore our brand new and improved space!

For more details, visit our website http://www.DrGPCR.com/Ecosystem/.

-------------------------------------------

Are you a #GPCR professional?

- Register to become a Virtual Cafe speaker

http://www.drgpcr.com/virtual-cafe/

-   Subscribe to our Monthly Newsletter

http://www.drgpcr.com/newsletter/

-   Listen and subscribe to #DrGPCR Podcasts

http://www.drgpcr.com/podcast/

-   Support #DrGPCR Ecosystem with your Donation.

http://www.drgpcr.com/sponsors/

-   Reserve your spots for the next #DrGPCR Virtual Cafe

http://www.drgpcr.com/virtual-cafe/

-   Watch recorded #DRGPCR Virtual Cafe presentations:

https://www.youtube.com/channel/UCJvKL3smMEEXBulKdgT_yCw

-   Share your feedback with us:

http://www.drgpcr.com/audience-survey/

Dr. Antony A. Boucard Jr. on the web Website LinkedIn Researchgate Loop Academia Pubmed Adhesion GPCR Consortium University of Haiti

About Dr. Antony A. Boucard Jr.

Dr. Antony Boucard joined the Université de Sherbrooke (Québec, Canada) as a B.S. student of the Biochemistry program in 1994 from which he graduated in 1997. It is then that his interest bloomed for the study of GPCRs while joining the group of Dr. Richard Leduc and Dr. Gaetan Guillemette in the Pharmacology department at the Université de Sherbrooke. He completed a master’s degree in 2000 and a Ph.D. degree in 2003 with a particular interest in the cardiovascular system by investigating the structure of the Angiotensin and Urotensin receptors through various biochemical approaches centered in the elucidation of ligand binding pocket determinants...

-------------------------------------------

We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.

Fill out the Ecosystem waitlist form today to be the first to explore our brand new and improved space!

For more details, visit our website http://www.DrGPCR.com/Ecosystem/.